Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Holtick U, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):361-72. doi: 10.1517/13543784.2011.553187. Epub 2011 Jan 22. Expert Opin Investig Drugs. 2011. PMID: 21254877 Review.
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours.
Weihrauch MR, Richly H, von Bergwelt-Baildon MS, Becker HJ, Schmidt M, Hacker UT, Shimabukuro-Vornhagen A, Holtick U, Nokay B, Schroff M, Wittig B, Scheulen ME. Weihrauch MR, et al. Among authors: von bergwelt baildon ms. Eur J Cancer. 2015 Jan;51(2):146-56. doi: 10.1016/j.ejca.2014.11.002. Epub 2014 Dec 2. Eur J Cancer. 2015. PMID: 25480557 Clinical Trial.
Overcoming tumor-mediated immunosuppression.
Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M. Schlößer HA, et al. Immunotherapy. 2014;6(9):973-88. doi: 10.2217/imt.14.58. Immunotherapy. 2014. PMID: 25341119 Review.
Nail dystrophy due to dose-intensive chemotherapy.
Weihrauch MR, von Bergwelt-Baildon MS. Weihrauch MR, et al. Int J Hematol. 2009 Jul;90(1):6-7. doi: 10.1007/s12185-009-0355-9. Epub 2009 Jun 20. Int J Hematol. 2009. PMID: 19543953 No abstract available.
CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential.
Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS. Kondo E, et al. Clin Exp Immunol. 2009 Feb;155(2):249-56. doi: 10.1111/j.1365-2249.2008.03820.x. Epub 2008 Nov 24. Clin Exp Immunol. 2009. PMID: 19040609 Free PMC article. Review.
289 results